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Abstract
Introduction: Blood lactate measurements can be used as an indicator of hemodynamic impairment and relate to
mortality in various forms of shock. Little is known at the moment concerning the clinical correlates of systemic
lactate in patients with ST-segment elevation myocardial infarction (STEMI).
Methods: To assess the relation of systemic arterial lactate levels in STEMI patients with clinical correlates at
presentation in the catheterization laboratory, we measured arterial lactate levels with a rapid point-of-care
technique, immediately following femoral sheath insertion. The study population (n= 1,176) was divided into
tertiles with lactate levels ≤1.1 (n = 410), 1.2 to 1.7 (n = 398) and ≥1.8 mmol/l (n = 368). We compared both
baseline characteristics and outcome measures of the three lactate groups.
Results: Factors independently associated with higher lactate levels were hypotension, heart rate, thrombolysis in
myocardial infarction (TIMI) flow 0 to 1, diabetes and non-smoking. Mortality at 30 days in the three groups was
2.0%, 1.5% and 6.5%. The latter group also showed lower blush grades and greater enzymatic infarct sizes. An intra
aortic balloon pump (IABP) was used more frequently in patients with higher lactate levels (4.2%, 7.6% and 14.7%).
Conclusions: In STEMI patients, impaired hemodynamics, worse TIMI flow and non-smoking were related to
increased arterial lactate levels. Higher lactate levels were independently related with 30-day mortality and an
overall worse response to percutaneous coronary intervention (PCI). In particular, acute mortality was related to
admission lactates ≥1.8 mmol/L. Point-of-care measurement of arterial lactate at admission in patients with STEMI
has the potential to improve acute risk stratification.
Introduction
The clinical value of circulating lactate has been exten-
sively demonstrated in critical care medicine [1]. Blood
lactate measurements can be used as an indicator of
hemodynamic impairment and as a predictor of out-
come in various forms of shock. In patients with cardio-
genic shock, several studies document marked elevations
in circulating lactate [2-9]. One of the most frequent
causes of circulatory shock is acute myocardial infarc-
tion. When tissue perfusion is impaired during acute
myocardial infarction, decreased oxygen delivery can
induce muscle cells to preferentially use glycolysis and
produce lactate from pyruvate, rather than oxidize pyru-
vate for mitochondrial energy production. In patients
with ischemic heart disease, the amount of lactate
released by the myocardium has been shown to be
related to the severity of coronary artery disease [10].
For patients with myocardial infarction, circulating
venous lactate levels have been shown to be increased
[11]. However, long transport times between blood sam-
pling and analysis may have led to falsely high results
[12]. Today rapid point-of-care analyzers are generally
available, enabling fast measurement of lactate levels.
The aim of this study was to determine the clinical
correlates of systemic arterial lactate levels in patients
with ST-elevation myocardial infarction (STEMI) prior
* Correspondence: r.p.vermeulen@thorax.umcg.nl
1Department of Cardiology, Thorax Center, University Medical Center
Groningen, University of Groningen, Hanzeplein 1 Groningen, The
Netherlands
Full list of author information is available at the end of the article
Vermeulen et al. Critical Care 2010, 14:R164
http://ccforum.com/content/14/5/R164
© 2010 Vermeulen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.to primary percutaneous coronary intervention (PCI)
using a rapid point-of-care analyzer. We investigated
whether hemodynamic parameters and other patient
characteristics at admission were related to lactate levels.
In addition, we related lactate levels at presentation to
30-day mortality, and other outcome measures such as
TIMI-flow (thrombolysis in myocardial infarction), peak
cardiac enzymes, ST-segment elevation resolution and
myocardial blush grade (MBG).
Materials and methods
Population
This was a prospective, observational study performed in
the catheterization laboratory of the University Medical
Center Groningen, The Netherlands. In The Netherlands,
primary PCI is the standard treatment for all patients
with STEMI. All patients with diagnosed STEMI within
the region of a hospital with interventional capacities
covered by a 90-minute radius by ambulance are either
transported directly to the catheterization laboratory or
referred by other non-interventional centers. Direct
transport for mechanical reperfusion therapy has repeat-
edly been proven to improve survival in STEMI patients
[13,14]. Before primary PCI, patients receive as premedi-
cation 5,000 IU of heparin, 900 mg acetyl salicylic acid
and 600 mg clopidogrel, either in the ambulance, at
presentation in the catheterization laboratory or in the
referring hospital.
We evaluated all patients who were diagnosed with
STEMI and treated with primary PCI in the catheteriza-
tion laboratory of our hospital from January 2006 to
September 2008. STEMI was diagnosed in patients with
symptoms suggesting acute myocardial ischemia lasting
more than 30 minutes, with the onset of symptoms less
than 12 hours previously, and with ST-segment eleva-
tion of more than 0.1 mV in two or more leads on the
ECG. Patients intubated prior to primary PCI after car-
diopulmonary resuscitation were excluded, because lac-
tate levels have been shown to be considerably elevated
in resuscitated patients [15,16]. The institutional review
board exempted the study from formal review.
Methods of measurement
To measure lactate levels an arterial blood sample was
taken directly after femoral sheath insertion using a self-
filling 1.5 ml PICO70 arterial sampler containing 60 IU
of lithium heparin (Radiometer, Copenhagen, Denmark).
Lactate was measured within three to four minutes on
an ABL 700/800 series analyzer (Radiometer) with a
lower detection limit of 0.1 mmol/L. In a whole blood
sample, the ABL analyzer converts lactate to pyruvate
and hydrogen peroxyde. The hydrogen peroxyde is then
reduced on a platinum anode, inducing a current pro-
portional to the lactate level in the sample. This method
has been shown to be fast and accurate, with results
comparable to those from central laboratory analyzers
[17,18]. During the procedure, the operator was not
informed of the result of the lactate measurement.
Patient characteristics and details about the procedure
and location of the infarction were taken from medical
charts and the database of the catheterization laboratory.
Blood pressure was measured in the ascending aorta.
Hypotension was defined as a systolic blood pressure of
≤90 mmHg [19]. The primary end point was death from
all causes at 30 days. ST-segment elevation resolution
was determined by comparing the 12-lead electrocardio-
gram (ECG) obtained directly prior to PCI to an ECG
made 30 to 60 minutes after PCI. The percentages of
resolution of the ST-segment elevation were classified
into three categories: >70%, 30 to 70% and <30%. MBG
after PCI was assessed as previously described [20], as
well as the maximum levels of creatine kinase (CK) [21]
and troponine T. As liver dysfunction can lead to
impaired lactate clearance, all patients were screened for
laboratory signs of liver dysfunction. We also specifically
looked at metformin use in diabetic patients as it is
known that metformin can lead to elevated lactate
levels. Coronary blood flow before and after primary
PCI was classified using the TIMI-flow grades. In the
description of the results, MBG and TIMI-flow were
dichotomized as 0 to 1 or 2 to 3. The use of IABP (intra
aortic balloon pump) was also recorded.
Statistical analysis
All data were analyzed using SPSS version 14 (SPSS,
Chicago, IL, USA). The study population was divided
into tertiles based on admission lactate level. To indicate
variation, we used means ± SD for normal distributions
or medians with interquartile ranges (Q25 to Q75) for
skewed distributions. Where appropriate, ANOVA,
Kruskal-Wallis H, Chi-square tests and ordinal regres-
sion tests were used to make comparisons among
the three groups of patients. To calculate multivariate
relations of lactate and other baseline characteristics
that were available before the first angiogram to 30-day
mortality, we used binary logistic regression analysis.
Lactate was entered into the analysis as a continuous
variable after lognormal transformation. The variables of
age, systolic blood pressure, heart rate, anterior infarc-
tion, diabetes, smoking and lactate were entered in a
single step. To calculate differences in Kaplan-Meier
curves we performed a logrank test (Mantel-Cox.). A
P-value of ≤.05 was considered statistically significant.
Results
Baseline clinical characteristics and lactate levels
From January 2006 to September 2008, 1,420 patients
with STEMI were treated with PCI at the University
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intubated (5%). For the 73 intubated patients, the med-
ian lactate level was 4.2 (1.5 to 7.9) with a range of 0.7
to 18.0 mmol/L, and mortality at 30 days was 40%.
In 13% of STEMI patients, an arterial lactate measure-
ment was not performed prior to the primary PCI.
Logistical reasons as technical maintenance of the ABL
analyzer or the analyzer being in calibration mode were
the cause of most of the missing cases. With regard to
baseline characteristics and 30-day mortality, missing
patients were similar to included patients. A total of
1,176 patients were included in the subsequent analyses.
Lactate levels were positively skewed, with a mean
l e v e lo f1 . 6 5±1 . 0 1m m o l / La n dam e d i a nl e v e lo f1 . 4
(1.0 to 2.0), range 0.5 to 10.9. Of the 1,176 included
patients, most were male (72%) and the mean age was
64 ± 13. Anterior infarction was present in 39% of
patients. Mean systolic blood pressure was 127 ± 27
mmHg, with 6% of patients presenting with hypoten-
sion. The mean heart rate was 78 ± 19 beats per minute.
TIMI-flow before PCI was rated as 0/1 in 66% of
patients. Angina was present in the days to weeks before
infarction in 50% of patients. In only three patients liver
dysfunction was observed. The study population was
divided into tertiles with lactate levels ≤1.1 (n= 410), 1.2
to 1.7 (n = 398) and ≥1.8 mmol/L (n = 368).
Table 1 displays the baseline characteristics for the
three lactate groups. In univariate analysis, patients in
the three groups were different with respect to heart
rate, incidence of hypotension and poor TIMI-flow, his-
tory of diabetes and history of smoking and admission
creatinine. After regression analysis, clinical characteris-
tics independently related to higher lactate levels were
hypotension (P < .001), higher heart rate (P = .002),
TIMI-flow 0 to 1 (P < .001), diabetes (P = .001) and
non-smoking (P < .001). Of 128 diabetic patients, 47
used metformin (37%). Lactate levels were higher in dia-
betic patients who used metformin compared to other
diabetic patients: 2.3 mmol/L vs 1.7 mmol/L (P = .005).
Lactate levels and outcome measures
At 30 days, overall mortality was 3.2% (n = 38). In-hos-
pital mortality was 2.2% (n = 26). The distribution of
30-day mortality in relation to admission lactates is dis-
played in Figure 1. For patients with lactate levels >4.0
mmol/L mortality showed a marked increase. The rela-
tions of the lactate tertiles with outcome measures are
displayed in Table 2. In the group with lactates ≥1.8
mmol/L mortality was increased (2.0 vs. 1.5 vs. 6.5%,
P < .001). In addition, for all other outcome measures
except TIMI-flow and percentage of ST-segment resolu-
tion a significant difference between the three groups
was found. When comparing patients in the first tertile
to those in the second tertile separately, we found that
the incidence of MBG 2/3 was lower in the second ter-
tile, and peak cardiac enzymes levels were higher. These
Table 1 Baseline characteristics, by tertile of lactate level
Lac ≤ 1.1 mmol/L
n= 410
Lac 1.2-1.7 mmol/L
n= 398
Lac ≥ 1.8 mmol/L
n= 368
P
Gender (male) 73.9 74.4 72.0 .738
Age 63 ± 13 63 ± 13 64 ± 12 .160
BMI 26 ± 4 27 ± 13 28 ± 5 .133
Hypotension 4.7 4.0 14.3 < .001 *
Heart rate 77 ± 16 78 ± 19 81 ± 21 .007 *
Anterior infarction 40.9 36.0 40.9 .273
Time in minutes from symptom onset to lactate measurement 176 (128 to 297) 160 (110 to 305) 173 (123 to 272) .217
TIMI-flow 0 to 1 56.7 71.3 69.5 < .001 *
Pre-infarct angina 53.8 48.4 46.7 .134
Risk factors:
Hypertension 31.7 38.2 41.3 .024
Diabetes 7.4 8.9 19.0 < .001 *
Hypercholesterolemia 32.5 37.0 31.5 .321
Smoking 56.5 47.4 40.2 < .001 *
Family History 42.9 45.2 46.6 .607
Previous myocardial infarction 9.7 11.2 12.0 .585
Previous PCI 8.6 7.2 9.0 .653
Previous CABG 2.5 2.4 3.2 .789
Admission Hemoglobin mmol/L 8.0 ± 1.1 8.2 ± 1.1 8.2 ± 1.2 .217
Creatinine μmol/L 77 (66 to 91) 80 (68 to 93) 83 (70 to 99) .002
*Independent correlates to admission lactate after regression analysis. Numbers as %, mean ± SD or median (Q25 to Q75); CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
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patients from the first tertile to patients from the last
tertile. IABP was needed in 4.2%, 7.6% and 14.7% of
patients in each tertile (P < .001).
The Kaplan-Meier curve in Figure 2 displays 30-day
proportional survival after primary PCI, stratified by the
three tertiles of admission lactate. The differences in
survival were significant (P < .001). We further exam-
ined the survival time of the non-survivors of the first
30 days. In the non-survivors from the first group, med-
ian survival in days was 13 (7 to 22), whereas for non-
survivors from the second group median survival was 7
(4 to 16). For non-survivors from the third group, med-
ian survival was one day (0 to 4) (P < .001).
In multivariate analysis, we determined if clinical
characteristics and risk factors readily available at pre-
sentation (age, systolic blood pressure, heart rate, ante-
rior infarction, diabetes, smoking and admission lactate)
were independently related to 30-day mortality. Table 3
shows the strength of each independent relation and
the level of significance. Lactate was independently
related to 30-day mortality, together with age, systolic
blood pressure, heart rate and smoking status. Similar
results except for smoking status were observed after
excluding diabetic patients from the multivariate
analysis.
Discussion
In this study we found that elevated arterial lactate
levels measured at presentation in the catheterization
laboratory prior to PCI were related to hypotension,
higher heart rate, poor TIMI-flow, diabetes and non-
smoking. Moreover, increased lactate levels were asso-
ciated with worse outcome measures including increased
30-day mortality, lower MBG, larger enzymatic infarct
size and increased use of IABP. Fifty percent of the
non-survivors with admission lactates ≥1.8 mmol/L died
within a day after PCI.
The additional value of an early lactate measurement
with regard to patient risk stratification is probably most
pronounced in patients with strongly elevated lactate
levels, as has been demonstrated in patients with sepsis
[22]. The sharp increase in mortality for patients with
admission lactates >4.0 mmol/L as seen in Figure 1 sug-
gests that in these patients intensified medical care, such
as IABP, may be considered, even after a successful PCI.
The analysis of survival times for the non-survivors
corroborates this observation. That admission lactate
had the strongest independent relation to mortality in a
model with other easily obtainable clinical parameters as
age, hypotension and heart rate, adds to our belief
that lactate measurement could be a part of standard
laboratory assessment of patients with STEMI at
admission in the hospital.
The finding that mildly elevated lactate levels were
associated with non-smoking, may be a reflection of the
smoker’s paradox [23,24]. Although age was not asso-
ciated with elevated lactate levels, we too observed that
smokers suffered from STEMI at a younger age than
non-smokers (58 vs. 69 years, P < .001).
It was already recognized in 1961 that circulating
lactate provides information about the hemodynamic
Figure 1 Distribution of 30-day mortality in relation to
admission lactates.
Table 2 Outcome parameters by tertile of lactate level
Lac ≤ 1.1 mmol/L (n = 410) Lac 1.2 to 1.7 mmol/L (n = 98) Lac ≥ 1.8 mmol/L (n = 68) P
30-day mortality 2.0 1.5 6.5 <.001
TIMI-flow 2 to 3 96.5 97.2 93.9 .055
Myocardial blush grade 2 to 3 82.0 76.8 67.2 <.001
ST-segment elevation resolution after PCI
>70% 64.4 59.0 54.5 .120
30 to 70% 23.5 24.2 28.2
<30% 12.1 16.8 17.3
CK total (peak, units/L) 789 (239 to 787) 1,175(542 to 2,239) 1,296(488 to 2,801) <.001
Troponine T (peak, μg/L) 2.13 (0.54 to 5.90) 3.63(1.45 to 7.11) 3.89(1.41 to 8.02) <.001
Numbers as %, mean ± SD or median (Q25 to Q75). CK, creatine kinase; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
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strongly related to survival in 142 patients with shock,
including 40 patients suffering from cardiogenic shock
[5]. Many studies in the emergency department and in
the intensive care unit have since demonstrated that
increased lactate levels are a strong predictor of early
and late mortality in patients with cardiogenic shock,
traumatic shock, sepsis and septic shock or liver failure
[27-29], as in non-diabetic patients with STEMI [30]. In
this last study, in 253 patients lactate was measured at
the CCU after PCI. Lactate, homeostatic model assess-
ment index (HOMA) and C-peptide were found to be
independent predictors of mortality in the CCU. Lactate
was also found to be higher in patients with increased
insulin resistance. These results indicate that also in our
study increased insulin resistance may have been causal
in both the increased lactates and the adverse outcome,
even in non-diabetics.
Another study that measured venous lactate levels in
patients with myocardial infarction found that two
hours after symptom onset, most patients had elevated
lactate levels [11]. Out of 64 patients with myocardial
infarction, 59 (92%) had venous lactate levels ≥1.5
mmol/L when measured in a central laboratory. Our
findings are in contrast with these results. Apart from
using arterial blood, another difference is that in our
study, all lactate measurements were performed within
three to four minutes from sampling. During transport,
lactate levels may rise 0.1 to 1.2 mmol/L in the first
hour, depending on the circumstances [12]. Prompt
measurement on a point-of-care analyzer in the cathe-
terization laboratory probably resulted in more accurate
and lower lactate levels compared to lactate measure-
ment in a central laboratory. The previous studies also
claimed on the basis of a few patients a high negative
predictive value of venous lactate for acute myocardial
infarction. In a much larger patient group, we found
that normal lactate levels occur in half of the patients
with confirmed STEMI.
These observations are in line with established physio-
logical principles. Lactate through pyruvate provides
under normal circumstances 10 to 40% of the myocardial
fuel supply, making the heart an important net consumer
of lactate. Impaired oxygen supply to parts of the myo-
cardium can turn the heart into a lactate producer
instead of a lactate consumer, as has been observed in
several models [10,31]. Hypotension, stress and glycome-
tabolic dysregulation [30] may also lead to increased lac-
tate levels. Our findings suggest further avenues of
interest. One single lactate measurement can provide
insight into the hemodynamic condition of the patient,
but the fact that patients with high patency rates have
lower lactate levels, could mean that after successful pri-
mary PCI, lactate levels normalize. Nowadays laboratory
equipment that promptly performs lactate measurements
is available to study the time course of lactate levels in
patients with STEMI.
Our study has a number of limitations. First, this
study was performed in a single center. Second, not all
STEMI patients were included: in 13% of patients, a lac-
tate measurement at presentation was not performed.
However, baseline characteristics and mortality figures
of missing patients were similar to included patients;
therefore, it is unlikely that our results were greatly
influenced by selection bias. Additional parameters such
as glucose, glycosylated hemoglobin (HbA1c) and brain
natriuretic peptide (NT-pro BNP) that may be related
with lactate levels were not available.
Conclusions
At admission, increasing arterial lactate levels were
associated with higher heart rate, hypotension, poor TIMI-
flow, diabetes and non-smoking. Higher lactate levels were
related to worse PCI outcome measures and increased
30-day mortality. Rapid point-of-care measurement of
Figure 2 Kaplan-Meier curve displaying 30-day proportional
survival after primary PCI. PCI, percutaneous coronary
intervention.
Table 3 Multivariate relations of clinical characteristics to
30-day mortality
Baseline characteristic Hazard Ratio 95% CI P
Age 1.10 1.16 to 1.65 <.001
Systolic blood pressure 0.96 0.95 to 0.98 <.001
Heart rate 1.02 1.00 to 1.04 .028
Anterior infarction 0.56 0.24 to 1.29 .174
Diabetes 0.64 0.22 to 1.89 .416
Smoking 0.31 0.12 to 0.82 .017
Lactate 2.52 1.12 to 5.66 .025
CI, confidence interval.
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the potential to improve acute risk stratification.
Key messages
￿ Point-of-care analysis enables fast and accurate
measurement of arterial lactate levels at the catheter-
ization laboratory.
￿ Lactate levels in STEMI patients at the catheteriza-
tion laboratory were related to hemodynamics and
TIMI flow.
￿ Increased lactate levels in STEMI patients were
associated with 30-day mortality.
￿ Half of the non-survivors with admission lactate
levels of ≥1.8 mmol/L died within a day after presen-
tation in the hospital.
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